Rifaximin-α use is associated with improved muscle mass in patients with cirrhosis
This study demonstrates a significant independent association between rifaximin-α therapy and muscle mass in patients with cirrhosis and HE. Prospective studies of rifaximin-α therapy examining its impact on sarcopenia are required to assess its potential therapeutic role in this cohort.
Authors
- Thomas Worland (ORCID: https://orcid.org/0000-0001-5122-5750)
- Roseanne Kimberley Chan (ORCID: https://orcid.org/0000-0003-2120-0792)
- Paul Gow (ORCID: https://orcid.org/0000-0001-6505-7233)
- Darren Wong (ORCID: https://orcid.org/0000-0003-1490-0547)
- Penelope Hey (ORCID: https://orcid.org/0000-0002-5219-0382)
- Ross Apostolov (ORCID: https://orcid.org/0000-0002-4827-8795)
- Marie J. Sinclair (ORCID: https://orcid.org/0000-0003-0657-3048)
Institutions
- Austin Health (AU)
Publication Details
- Journal
- World Journal of Hepatology
- Published
- 2025-04-25
- DOI
- https://doi.org/10.4254/wjh.v17.i4.104056
- Citations
- 1
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 1.32